Michael G. Ison, MD MS

Bird flu antibodies found in cow in the Netherlands, a first outside of U.S. Dead cat led to discovery, but officials stress no further spread of H5N1 has been detected

www.science.org/content/arti...

But worth it for piece of mind.

It’s actually hard to get the vaccine - we got ours but it required pre-paying for the doses and having delays in getting them delivered to the pharmacy. Total cost $900 with GoodRx and 3 doses so takes time. Doable but expensive and takes a lot of effort to arrange (in my experience).

Hospital‐Acquired Respiratory Viral Infections (HA‐RVIs) over 10 Years Disproportionally Affect the Immunocompromised The incidence of HA-Flu/RSV/PIV is associated with patients at high risk of developing RVI complications such as oncology and SCT patients and that most HA cases occur during winter respiratory virus...

So happy to see this paper out after a lot of persistence from Shardul Rathod @hannahnam.bsky.social @ucirvine.bsky.social.

Over a 10 yr period, 6.6% of Flu cases, 12.2% of RSV cases, and 10.9% of PIV cases were Hosp-Acquired. Most in ICH.

onlinelibrary.wiley.com/doi/10.1111/...

I had the HUGE honor of being the 40th Forbes Fellow - when I was the previous awardees, I was truly humbled. The ID community is incredible in Melbourne. @monashuniversity.bsky.social @unimelb.bsky.social @thedohertyinst.bsky.social @trubianojason.bsky.social @bradgardiner.bsky.social

Aicuris Announces Pritelivir Met Primary Endpoint in Immunocompromised Herpes Simplex Virus-infected Patients in Phase 3 Pivotal Trial - Aicuris Aicuris today announced that the Phase 3 trial of its lead candidate pritelivir has met its primary and secondary endpoint. The aim of the trail was to evaluate

Important Ongoing Studies where we have or will have publications soon:

Pritelivir for refractory or resistant HSV (presented @idweek.bsky.social by @kottonnelson.bsky.social): www.aicuris.com/press-releas...

CD388 for prevention of influenza: www.cidara.com/news/cidara-...

Efficacy, safety, and immunogenicity of the AS01E-adjuvanted respiratory syncytial virus prefusion F protein vaccine (RSVPreF3 OA) in older adults over three respiratory syncytial virus seasons (AReSV... A single RSVPreF3 OA dose was efficacious against RSV-LRTD over three RSV seasons in people aged 60 years or older, despite a decrease in efficacy over time. Further research is needed to establish th...

Results from season 3 of the GSK RSV Vaccine (NOTE - I was the lead author so I’m biased on this one)
www.thelancet.com/journals/lan...

Two trials on tecovirimat for Mpox and the need to consider research in context of EUA medications
www.nejm.org/doi/full/10....
evidence.nejm.org/doi/full/10....

Efficacy of Baloxavir Treatment in Preventing Transmission of Influenza | NEJM Baloxavir marboxil (baloxavir) rapidly reduces influenza virus shedding, which suggests that it may reduce transmission. Studies of treatment with neuraminidase inhibitors have not shown sufficient...

Study of baloxavir to prevent household transmission of influenza
www.nejm.org/doi/full/10....

Two studies of monoclonals for RSV prevention
www.nejm.org/doi/full/10....
www.thelancet.com/journals/lan...

Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons | NEJM Twice-yearly subcutaneous lenacapavir has been shown to be efficacious for prevention of human immunodeficiency virus (HIV) infection in cisgender women. The efficacy of lenacapavir for preexposure...

Two trials on lenacapravir for prevention of HIV
www.nejm.org/doi/full/10....
www.nejm.org/doi/10.1056/...

Two trials on high dose influenza vaccine
jamanetwork.com/journals/jam...
www.nejm.org/doi/abs/10.1...
www.nejm.org/doi/abs/10.1...

Due to the USG Shutdown, I wasn’t able to attend or present @idweek.bsky.social. I was supposed to give the talk on top viral studies that will impact your practice. Here are the papers I was going to highlight:

See next posts

Thanks to Lara Danziger-Isakov for doing the talk.

Slides:
www.dropbox.com/scl/fi/nj1z8...

Due to the US Government Shutdown, I will not be able to atted @IDWeek.bsky.social #IDWeek2025. I had worked on my 2 invited talks and so will share them.

My first talk was going to be about the epidemiology and clinical course of respiratory viral infections in the immunocompromised.

Influenza Antivirals for Prevention and Treatment in Immunocompromised People Antivirals are an important backbone for the prevention and treatment of influenza in immunocompromised individuals, who are prone to prolonged viral shedd

Included in the supplement is an important paper about application of antivirals in immunocompromised patients @mady247.bsky.social

academic.oup.com/jid/article/...

Volume 232 Issue Supplement_3 | The Journal of Infectious Diseases | Oxford Academic An official journal of the Infectious Diseases Society of America. Publishes research results on microbiology, immunology, and epidemiology; pathogenesis, diagnosis, and treatment of infectious diseas...

Excited to see the “Advances in Influenza Therapeutics” supplement out in @jidjournal.bsky.social - led by Fred Hayden and Rich Whitley, this supplement reviews what we know about antivirals and how they should be used for influenza.

academic.oup.com/jid/issue/23...

Do you focus on HSCT/Oncology ID? Want to be part of the editorial team of @thetxidjournal.bsky.social? Please apply by October 17 for an open position as outlined in this link!

check out our review of donor-derived infections in heart & lung transplant recipients! was a pleasure working with
@michaelisonmd.bsky.social
on this! #TxID doi.org/10.1016/j.jh...

The ISRV AVG meeting kicked of by Fred Hayden giving the 2nd Roberts/Tisdale lecture on the clinical implications of antiviral resistance.

Identification of immune signatures associated with both SARS-CoV-2 infection and lung transplantation Lung transplantation (lung-tx) offers the last life-saving option for patients with COVID-19-associated lung injury (CALI). We show that the RBD-speci…

Excited to have this paper out! Demonstrates that the recipients of lung 🫁 tx for COVID-Associated Lung Injury (CALI) loose humoral protection and have unique cellular immune responses.

www.sciencedirect.com/science/arti...

AJT’S new ID blog, TxIDExchange, is dedicated to sharing the latest ID updates, research, and guidelines relevant to the transplant community. We’re soliciting blog posts and comments from you and your colleagues and encourage you to participate.

ajt-transplant-id-exchange.squarespace.com

AJT Transplant ID Exchange

Don't miss the new @amjtransplant.bsky.social #TxID blog led by Emily Blumberg ajt-transplant-id-exchange.squarespace.com #wtc2025 @ast-idcop.bsky.social @ast-tyfcop.bsky.social @astinfo.bsky.social

Excited to head to San Francisco for #WTC2025 @ast-idcop.bsky.social

Michael Woodward presented on utility of FMT in ICHs - can reduce risk of recurrent C diff and MDRO infections - cost, availability and lack of guidance are limiting application @fredhutch 5th Symposium on ID in ICHs.

www.science.org/doi/10.1126/...

Likewise, screening for FQ resistance may inform what breakthrough infections will occur and optimize early management.

Mike Satlin gave an incredible review of MDR-GBR. These challenging bacteria cause freq infections and screening for can inform management of F&N @fredhutch.bsky.social 5th Symposium on ID in ICHs.

Jay Fishman provided the keynote on Xenotransplantation- major progress but many unknowns- thankfully formal clinical trials will help inform optimal approach @fredhutch.bsky.social 5th Symposium on ID in ICHs.

Erika Kampouri provided a masterful review of infections after CAR-T and the impact of CMV and HHV6 in these patients - HHV6 CNS disease rare, CMV needs more data to confirm optimal management. @fredhutch.bsky.social 5th Symposium on ID in ICHs

onlinelibrary.wiley.com/doi/10.1111/...

The future may be using the tool to look at pathogen and host response in the same assay - multiple examples shown that the combined approach provided answers that wouldn’t have been identified.

Charles Chiu @UCSF gave an amazing lecture on mNGS in immunocompromised- while helpful, limitations exist and must be recognized to interpret the results.

Amazing talk on aging and infection Maheen Abidi - many questions and need for data to inform management approaches. @fredhutch.bsky.social Symposium of Infections in ICH

Hans Hirsch provided a master class in BKV as the keynote for the 5th @fredhutch.bsky.social Symposium on Infections in ICH. Studies have advanced our understanding of pathogens and management - but many questions remain.